Eli Lilly and Company (LLY MU) stock market data APIs
€653.7867
4(0.6%)
as of July 4, 2025
Try our APIs with
free plan!
Eli Lilly and Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LLY.MU.
Prev. Close
653.7867
Open
657.7819
High
654.9208
Low
653.7867
52 wk Range
620.7153-887.1639
Market Cap
206 794 M
EPS
3.34
Dividends (Yield)
0.0148
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-01
- EPS/Forecast: 3.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and Ozempic f...
UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro
Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the p...
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo. Continue Reading View Comments
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
